AbCellera Biologics Inc.
ABCL
Rangering i aksjer
#4179
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Aksjekurs
$11.85
Sist synkronisert: 2026-10-16
Markedsverdi
$3.84B
Endring (1 dag)
-6.59%
Endring (1 år)
111.90%
Land
CA
Handel AbCellera Biologics Inc. (ABCL)
Kategori
Healthcare
EPS for AbCellera Biologics Inc. (ABCL)
EPS per June 2026 TTM: $-0.54
Ifølge de siste økonomiske rapportene og aksjekursen til AbCellera Biologics Inc. er selskapets nåværende EPS (TTM) $-0.54. Ved slutten av 2023 hadde selskapet en EPS på $-0.51, en nedgang sammenlignet med EPS-en i 2022 som var $0.56.
EPS-historikk for AbCellera Biologics Inc. fra 2018 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-0.54 | -1.82% |
| 2024 | $-0.55 | 7.84% |
| 2023 | $-0.51 | -191.07% |
| 2022 | $0.56 | 0.00% |
| 2021 | $0.56 | 75.00% |
| 2020 | $0.32 | -3,206.80% |
| 2019 | $-0.01 | -615.00% |
| 2018 | 0.00 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -3,307.41% |
US
|
|
| $-7.98 | 1,377.78% |
US
|
|
| $-5.29 | 879.63% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -5,237.04% |
NL
|
